-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
544px;white-space:normal;background-color:#FFFFFF;caret-color:#333333;font-family:mp-quote, -apple-system-font, BlinkMacSystemFont, Arial, sans-serif;line-height:2em;overflow-wrap:break-word ;">
544px;white-space:normal;background-color:#FFFFFF;caret-color:#333333;font-family:mp-quote, -apple-system-font, BlinkMacSystemFont, Arial, sans-serif;line-height:2em;overflow-wrap:break-word ;"> Recently, "Hutchison China MediTech (or Chi-Med)" and "Hutchison MediPharma", an innovative drug research and development business brand responsible for the development and commercialization of anti-tumor drugs, have been integrated into one A unified and complete corporate brand.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;caret-color:#333333;font-family:mp-quote, -apple-system-font, BlinkMacSystemFont, Arial, sans-serif;text-size-adjust:auto;line-height:2em;overflow-wrap:break-word ;">544px;white-space:normal;background-color:#FFFFFF;text-align:center;line-height:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;caret-color:#333333;font-family:mp-quote, -apple-system-font, BlinkMacSystemFont, Arial, sans-serif;text-size-adjust:auto;line-height:2em;overflow-wrap:break-word ;">544px;text-align:justify;white-space:normal;background-color:#FFFFFF;caret-color:#333333;font-family:mp-quote, -apple-system-font, BlinkMacSystemFont, Arial, sans-serif;text-size-adjust:auto;line-height:2em;overflow-wrap:break-word ;">The new English name "HUTCHMED" will immediately replace the original abbreviation "Chi-Med", and the Chinese name "" will remain unchanged.
The company plans to formally change the name of the group at the annual general meeting in April 2021; the official website address will also be changed tostyle='margin:0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;font-size:15px;font-family:, "Microsoft YaHei";'>The new English name "HUTCHMED" will immediately replace the original abbreviation "Chi-Med", and the Chinese name "" will remain unchanged.
The company plans to formally change the name of the group at the annual general meeting in April 2021; the official website address will also be changed tostyle='margin:0px;padding:0px;max-width:100%;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:17px;letter-spacing:0.
544px;text-align:justify;text-indent:0em;white-space:normal;background-color:#FFFFFF;min-height:1em;line-height:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;caret-color:#333333;font-family:, "Microsoft YaHei";'> * = Unaudited; ** = represents the total sales to third parties (data provided by Eli Lilly); *** = represents the production costs, commercialization service fees, and royalties paid by Eli Lilly to Hutchison Medicine and Sales to third parties invoiced by Hutchison Medicine.
Su Taida ®(Cable where imatinib) (surufatinib / HMPL-012) on the market - in mid-January 2021, approved after three weeks on the market in China for the treatment of advanced non-pancreatic neuroendocrine tumors (NET) patients.
Su Taida ® the first two months after listing (January 2021 to February) unaudited sales of $ 4.
9 million; and the establishment of a US commercial team - in New Jersey recruited senior management team, responsible for all cable Preparations for the listing of tinib in the United States.
Sofantinib may be approved in the United States at the end of 2021 or early 2022.
Su Taida ® (Cable where imatinib) (surufatinib / HMPL-012) on the market - in mid-January 2021, approved after three weeks on the market in China for the treatment of advanced non-pancreatic neuroendocrine tumors (NET) patients.
Su Taida ® the first two months after listing (January 2021 to February) unaudited sales of $ 4.
9 million; and the establishment of a US commercial team - in New Jersey recruited senior management team, responsible for all cable Preparations for the listing of tinib in the United States.
Sofantinib may be approved in the United States at the end of 2021 or early 2022.
Su Taida ® (Cable where imatinib) (surufatinib / HMPL-012) on the market - in mid-January 2021, approved after three weeks on the market in China for the treatment of advanced non-pancreatic neuroendocrine tumors (NET) patients.
Su Taida ® the first two months after listing (January 2021 to February) unaudited sales of $ 4.
9 million; and ® ® established a US commercial team - in New Jersey recruited senior management team, responsible for Preparations for Sofatinib's listing in the United States.
Sofantinib may be approved in the United States at the end of 2021 or early 2022.
